DEUTERIERTE IVACAFTOR-DERIVATE

European patent · EP2709986 · In force

Register entry

Publication number
EP2709986
Application number
EP12725197
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
May 17, 2012
Published
Mar 26, 2014
Granted
Mar 22, 2017
Protection ends at the latest
May 16, 2032
Next annual fee due
May 31, 2027
IPC classes
C07D 215/56 (2006.01)
C07B 59/00 (2006.01)
A61K 31/47 (2006.01)
A61P 11/12 (2006.01)
Priority
US 201161487497 P 18.05.2011
PCT application
PCT/US2012/038297 17.05.2012
PCT publication
WO2012/158885 22.11.2012
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jun 1, 2026

    Change

    Published in Swissreg on 01.06.2026

  2. Jun 1, 2025

    Change

    Published in Swissreg on 01.06.2025

  3. Jun 2, 2024

    Change

    Published in Swissreg on 02.06.2024

  4. Jun 9, 2023

    Change

    Published in Swissreg on 09.06.2023

  5. Apr 15, 2020

    Transferred

    Owner
    Concert Pharmaceuticals Inc., 99 Hayden Avenue, Lexington, MA 02421, USA → Vertex Pharmaceuticals (Europe) Limited, 2 Kingdom Street, London W2 6BD, United Kingdom

    Published in Swissreg on 15.04.2020

  6. Apr 21, 2017

    Agent entered

    Representative
    Isler & Pedrazzini AG, Postfach 1772, 8027 Zürich

    Published in Swissreg on 21.04.2017

  7. Mar 22, 2017

    Granted

    Published in Swissreg on 22.03.2017

Parties

Inventor

MORGAN, Adam, J.

Ashland MA 01721, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.